Recent

% | $
Quotes you view appear here for quick access.

Exelixis, Inc. Message Board

  • stocklooking stocklooking Mar 18, 2013 7:51 PM Flag

    a question about EXAM events

    330 patients, cabozantinib 140 mg (n = 219) or placebo (n = 111)
    need 217 events to do OS analysis,
    projecting that later in this year or in 2014.
    the interim analysis recall we had only 44% of the events that are required for the final analysis(that was about 95 events at interim analysis)
    The 1-year PFS rate was 47.3% for the cabozantinib arms versus 7.2% with placebo. Data for overall survival (OS), are not yet mature

    So, it takes about 1.5 years for another 122 events to happen. It seems that after some point of time, the event rate drop dramatically no matter if progressed or not, on cabo or not. Is my understanding correct?

 
EXEL
2.60+0.03(+1.17%)Apr 1 4:00 PMEDT